The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAgronomics Regulatory News (ANIC)

Share Price Information for Agronomics (ANIC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 8.55
Bid: 8.50
Ask: 8.60
Change: -0.14 (-1.59%)
Spread: 0.10 (1.176%)
Open: 8.58
High: 8.66
Low: 8.55
Prev. Close: 8.80
ANIC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Share Buyback Programme announced

22 Sep 2023 07:00

RNS Number : 2676N
Agronomics Limited
22 September 2023
 

22 September 2023

Agronomics Limited

("Agronomics" or the "Company")

Share Buyback Programme announced

The Board of Agronomics announces that it will execute an on-market Share buyback programme for an aggregate amount of up to £3 million (the "Buyback Programme"). The term of the Buyback Programme shall be 6 months, commencing on 2 October 2023. The Company intends to cancel any repurchased Shares under the programme unless used to cover obligations under share-based remuneration arrangements.

The Board notes that the price of the Company's Shares is currently significantly below the last reported net asset value per share ("NAV Per Share") of 15.8 pence and believes that the Buyback Programme will help reduce this discount. In particular, as reported on 2 August 2023, the Company's unaudited NAV Per Share as at 30 June 2023 was 15.8 pence per share (whereas the price of the Company's shares at close of business on 19 September 2023, was 9.9 pence per share, a discount of approximately 37.3%). The Company reports NAV Per Share on a quarterly basis within 90 days of the end of each calendar quarter ("Quarterly NAV Statement").

The Buyback Programme will be executed within the limitations of the existing authority in the Company's Articles of Association. The Board will authorise each buyback transaction during the Buyback Programme which will be undertaken by Cavendish Securities Plc as the Company's joint broker and each such transaction will be reported and announced once executed.

The Company has determined that in conducting the Buyback Programme it will not rely on the safe harbour conditions for trading set out in Article 3(2) and Article 3(3) of the Commission Delegated Regulation (EU) 2016/1052 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018) and, as such, the Company may purchase on any trading day materially in excess of 25 per cent of the average daily volume in the 20 trading days preceding the date on which the purchase is carried out.

The terms of the Buyback Programme are set out below:

Name of Programme

2023 Share Buyback Programme

Purpose of the Programme

To reduce the capital of the issuer

Duration of the Programme

2 October 2023 to 29 March 2024

Maximum amount allocated to the Programme

£3.0 million

Maximum monthly amount allocated to Programme

£500,000

Maximum price

 

The higher of:

a) the price of the last independent trade; and

b) the highest current independent purchase bid on the trading venue where the purchase is carried out,

SAVE THAT no share shall be bought back by the Company at a price per share higher than 75% of the last reported NAV Per Share published in the Company's most recent Quarterly NAV Statement.

There is no guarantee that the Buyback Programme will be implemented in full or that any purchases will be made.

As at the time of this announcement, the Company's total issued share capital consists of 993,153,870Ordinary Shares with one voting right per share. The Company does not hold any Ordinary Shares in treasury, therefore, the total number of Ordinary Shares carrying voting rights is 993,153,870.

The above figure 993,153,870may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

About Agronomics

Agronomics is the leading listed venture capital firm with a focus on cellular agriculture. The Company has established a portfolio of over 20 companies at the Pre-Seed to Series C stage in this rapidly advancing sector. It seeks to secure minority stakes in companies owning technologies with defensible intellectual property that offer new ways of producing food and materials with a focus on products historically derived from animals. These technologies are driving a major disruption in agriculture, offering solutions to improve sustainability, as well as addressing human health, animal welfare and environmental damage. This disruption will decouple supply chains from the environment and animals, as well as being fundamental to feeding the world's expanding population.

About Cellular Agriculture

Cellular Agriculture is the production of agriculture products directly from cells, as opposed to raising an animal for slaughter or growing crops. This encompasses cell culture to produce cultivated meat and materials, and fermentation processes that harness a combination of molecular biology, synthetic biology, tissue engineering and biotechnology to massively simplify production methods in a sustainable manner.

Over the coming decades, the source of the world's food supply traditionally derived from conventional agriculture is going to change dramatically. We have already witnessed the first wave of this shift with the consumer adoption of plant-based alternative proteins but today, we are on the cusp of an even bigger wave of change. This is being facilitated by advances in cellular agriculture. This change is necessary, given scientists' claims that if we maintain existing animal protein consumption patterns, then we will not meet the Paris Agreement's goal of limiting warming to 1.5.

AT Kearney, a global consultancy firm, projects that cultivated meat's market share will reach 35% by 2040. This combined with the Good Food Institute's estimate that a US $1.8 trillion investment will be required in order to produce just 10% of the world's protein using this technology, means that we are on the cusp of a multi-decade flow of capital to build out manufacturing facilities. Funding in the field of cellular agriculture is accelerating, however, still, less than US$ 5 billion has been invested worldwide since the industry's inception in 2016.

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014, as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

For further information please contact:

Agronomics Limited

Beaumont Cornish Limited

Canaccord Genuity Limited

Cavendish Securities Plc

Peterhouse Capital Limited

SEC Newgate

The Company

Nomad

Joint Broker

Joint Broker

Joint Broker

Public Relations

Richard Reed

Denham Eke

Roland Cornish

James Biddle

Andrew Potts

Harry Rees

Alex Aylen (Head of Equities)

Giles Balleny

Michael Johnson

Lucy Williams

Charles Goodfellow

Bob Huxford

George Esmond

Anthony Hughes

Alice Cho

+44 (0) 1624 639396

info@agronomics.im

+44 (0) 207 628 3396

+44 (0) 207 523 8000

+44 (0) 207 397 8900

+44 (0) 207 469 0936

agronomics@secnewgate.co.uk

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
POSNKDBPQBKDNCB
Date   Source Headline
18th Jul 20237:00 amRNSFormo Successful Tasting Event
18th Jul 20237:00 amRNSPortfolio Company Update: Galy Co. Update
11th Jul 202311:33 amRNSExercise of Warrants and TVR
22nd Jun 20231:06 pmRNSCultivated Meat Approved for Sale in the US
22nd Jun 202312:42 pmRNSPortfolio Company CellX Raises US$ 6.5 million
22nd Jun 202310:00 amRNSGood Dog Food raises investment from Pets at Home
16th Jun 20237:00 amRNSUSDA Gives First Label Approval to Lab Grown Meat
15th Jun 20237:00 amRNSAUD 2.5 million investment in HydGene Renewables
14th Jun 20237:00 amRNSAgronomics Appoints Comms Consultancy
1st Jun 20237:00 amRNSReplacement Warrant Final Exercise Dates Extension
31st May 20237:00 amRNSExtension of Warrant Final Exercise Dates
9th May 20232:08 pmRNSDirectors' Dealings
4th May 20237:00 amRNSInvestee Company Update: Good Dog Food
2nd May 202311:38 amRNSNet Asset Value calculation as at 31 March 2023
14th Apr 202310:19 amRNSExercise of Warrants and TVR
12th Apr 202312:00 pmRNSInvestee Company Update: Liberation Labs
28th Mar 20237:00 amRNSDirector/PDMR Shareholding
27th Mar 202311:50 amRNSDirector/PDMR Shareholding
16th Mar 20237:00 amRNSFood Fermentation Europe launches
15th Mar 20237:00 amRNSDirectors’ interests in shares
10th Mar 20237:15 amRNSEdison issues update on Agronomics (ANIC)
2nd Mar 20235:50 pmRNSHolding(s) in Company
23rd Feb 20238:00 amRNSANIC invests in Wild Microbes US$3.3m Financing
23rd Feb 20237:00 amRNSAgronomics Welcomes Marisa Drew as a Director
20th Feb 20237:00 amRNSPrecision Fermentation Alliance Formed
9th Feb 20239:00 amRNSAgronomics February 2023 Newsletter
8th Feb 20237:00 amRNSUnaudited Interim Results
7th Feb 20234:49 pmRNSInvestee Company Update: CellX
2nd Feb 202311:04 amRNSResult of AGM
25th Jan 20237:00 amRNSNet Asset Value calculation at 31 December 2022
25th Jan 20237:00 amRNSInvestee company Update: Liberation Labs
4th Jan 20237:00 amRNSPerformance Shares issued to Shellbay Investments
30th Dec 202212:00 pmRNSPortfolio Company Update: Liberation Labs
23rd Dec 20227:00 amRNSSolar Foods receives Euro34 million in grant
20th Dec 20229:00 amRNSFinal Results
5th Dec 20229:18 amRNSInvestee Company Update: Clean Food Group
5th Dec 20227:00 amRNSFurther Investment in Liberation Labs Seed Round
28th Nov 20227:00 amRNSHolding(s) in Company
23rd Nov 20225:59 pmRNSHolding(s) in Company
17th Nov 20227:30 amRNSFirst Cultivated Meat Company gets FDA approval
3rd Nov 20227:00 amRNSAgronomics Capital Markets Day 3rd November
27th Oct 202212:02 pmRNSDirector Dealings
26th Oct 20229:30 amRNSPortfolio Company Solar Foods Update
20th Oct 20227:00 amRNSInvestment in Liberation Labs US$ 20m fundraise
19th Oct 20229:00 amRNSAgronomics October 2022 Newsletter
19th Oct 20227:00 amRNSNet Asset Value calculation to 30 September 2022
12th Oct 20228:53 amRNSHolding(s) in Company
11th Oct 20227:00 amRNSExercise of Warrants & TVR
10th Oct 20227:00 amRNSPortfolio Company Meatable Update
6th Oct 20227:00 amRNSPortfolio Company VitroLabs Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.